| Ytd | -47.33% | |
| 1y | -37.98% |
| Open | 7.68 | Prev Close | 7.56 | Low | 6.54 | High | 7.68 | Mkt Cap | 151.33M |
| Vol | 107.42K | Avg Vol | 270.41K | EPS | -3.21 | P/E | -2.15 | Forward P/E | N/A |
| Beta | 3.81 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 5.39 | 200-d Avg | 8.37 | 1yr Est | 0.00 |
AARD News
Shares of Aardvark Therapeutics, Inc. (NASDAQ: AARD - Get Free Report) have earned an average rating
SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NA
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- On May 15, 2026, investors in Aardvark Therapeutics
SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NA
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD)
Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark
SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (N
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug C
SAN FRANCISCO, June 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (N
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutic
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NA
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NA
SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NA
Aardvark Therapeutics, Inc. faces a pivotal regulatory setback as the FDA placed a clinical hold on
Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & U
Aardvark Therapeutics Inc. (NASDAQ:AARD) said the U.S. Food and Drug Administration (FDA) has placed
Top Wall Street analysts upgraded RXO, BWXT, and Timken stocks with higher price targets. See other
Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out
Figma Inc (NYSE: FIG) shares rose 10.6% in pre-market trading after beating Q1 revenue and earnings
Aardvark Therapeutics on Thursday said the U.S. Food and Drug Administration placed a full clinical
Wall Street analysts changed ratings on top companies. See full list at benzinga.com/analyst-stock-r
Wall Street analysts changed ratings on top stocks. Check out analyst ratings page for full list. NV
Wall Street analysts changed outlook on top names: BTIG cut CRWD PT, Piper Sandler cut BSY PT, RBC C
AMTD Digital Inc - ADR (NYSE: HKD) jumped 24.4% in pre-market trading after reporting a 565.7% incre
